Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy

Pai, Reetesh K.; Pai, Rish K.

doi:10.1038/modpathol.2017.87

Cited by 32 publications

(18 citation statements)

References 135 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LNs were harvested and either completely embedded if the diameter was <0.5 cm or, otherwise, one section was taken of the largest diameter. In line with previous reports on oesophageal and gastric cancers, hyaline fibrosis, acellular mucin and the presence of sheets of foamy histiocytes were considered as characteristic signs of tumour regression [9][10][11]20]. In cases where no visible tumour was detected but regressive changes were present, an additional three step sections were performed similar to the approach for the primary tumour [9].…”

Section: Evaluation Of Tumour Regression In Ln Metastasesmentioning

confidence: 88%

“…Regression of the primary tumour is associated with favourable outcome after neoadjuvant therapy followed by surgery in gastric cancer [8]. Histopathological assessment of tumour regression of gastrointestinal carcinomas is usually performed on the primary tumours and the most commonly used grading systems solely include the evaluation of regression at the site of the primary tumour [9,10]. Regressive changes, however, can also be observed in LN metastases [11][12][13] [12,[15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas

Reim

Novotny

Frieß

et al. 2020

The Journal of Pathology CR

View full text Add to dashboard Cite

The presence of lymph node (LN) metastases is one of the most important negative prognostic factors in upper gastrointestinal carcinomas. Tumour regression similar to that in primary tumours can be observed in LN metastases after neoadjuvant therapy. We evaluated the prognostic impact of histological regression in LNs in 480 adenocarcinomas of the stomach and gastro-oesophageal junction after neoadjuvant chemotherapy. Regressive changes in LNs (nodular and/or hyaline fibrosis, sheets of foamy histiocytes or acellular mucin) were assessed by histology. In total, regressive changes were observed in 128 of 480 patients. LNs were categorised according to the absence or presence of both residual tumour and regressive changes (LN−/+ and Reg−/+). 139 cases were LN−/Reg−, 28 cases without viable LN metastases revealed regressive changes (LN−/Reg+), 100 of 313 cases with LN metastases showed regressive changes (LN+/Reg+), and 213 of 313 metastatic LN had no signs of regression (LN+/Reg−). Overall, LN/Reg categorisation correlated with overall survival with the best prognosis for LN−/Reg− and the worst prognosis for LN+/Reg− (p < 0.001). LN−/Reg+ cases had a nearly significant better outcome than LN+/Reg+ (p = 0.054) and the latter had a significantly better prognosis than LN+/Reg− (p = 0.01). The LN/Reg categorisation was also an independent prognostic factor in multivariate analysis (HR = 1.23; 95% CI 1.1-1.38; p < 0.001). We conclude that the presence of regressive changes after neoadjuvant treatment in LNs and LN metastases of gastric and gastrooesophageal junction cancers is a relevant prognostic factor.

show abstract

Section: Evaluation Of Tumour Regression In Ln Metastasesmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas

Reim

Novotny

Frieß

et al. 2020

The Journal of Pathology CR

View full text Add to dashboard Cite

show abstract

“…If no residual tumor is identified in the initial sections, then the entire tumor bed should be submitted for microscopic examination. 79,80 Pai and Pai 80 noticed that tumor in the duodenal wall is often not affected by neoadjuvant therapy; therefore, sampling of duodenal wall adjacent to the tumor bed should be performed.…”

Section: Update Of Tumor Staging and Surgical Pathology Report Of Pdacmentioning

confidence: 99%

Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions

Ren

Suriawinata

2019

The American Journal of Pathology

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is one of the most aggressive malignant neoplasms with poor outcomes. At the time of diagnosis, the disease is usually at an advanced stage and only a minority is eligible for surgical resection. To improve the prognosis, it is essential to diagnose and treat the disease in an early stage before its progression into an invasive disease. This article reviews clinical features, histopathology, cytopathology, and molecular alterations of pancreatic ductal adenocarcinoma and its precursors. Moreover, we review a recently updated two-tier classification system for precursor lesions, new findings in premalignant cystic neoplasms, and recently updated staging criteria for invasive carcinoma based on the Cancer Staging Manual, eighth edition, from the American Joint Committee on Cancer. Finally, we discuss the potential clinical applications of the rapidly growing molecular and genetic information of pancreatic cancer and its precursors. (Am J Pathol 2019, 189: 9e21; https://

show abstract

“…Globally, pancreatic carcinoma (PC) is the fourth leading cause of cancer-related death, which is one of the most aggressive tumors [1, 2]. Currently, complete tumor resection is considered the only potential treatment for PC that results in a complete cure [3].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Long non-coding RNA MACC1-AS1 promoted pancreatic carcinoma progression through activation of PAX8/NOTCH1 signaling pathway

Chen

et al. 2019

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Accumulated evidences have demonstrated that long non-coding RNAs (lncRNAs) are dysregulated and correlate with the pathophysiological basis of malignant tumors. The objective of this research is to uncover the possible molecular mechanism of MACC1-AS1 regarding the regulation of pancreatic carcinoma (PC) metastasis. Methods lncRNA microarray and qRT-PCR were applied to identify differentially expressed lncRNA profile in PC. The function and role of MACC1-AS1 in PC were assessed via in vitro as well as in vivo assays. Luciferase analyses, RNA immunoprecipitation, and RNA pull-down were performed to determined the underlying MACC1-AS1 mechanisms. Results Numbers of differentially expressed lncRNAs in PC were identified via lncRNA microarrays, among which MACC1-AS1 was revealed as the most abundant lncRNA. The upregulation of MACC1-AS1 in PC was further confirmed in two expanded PC cohorts, which showed that MACC1-AS1 expression was upregulated in those PC patients with poor survival. Functionally, knockdown of MACC1-AS1 inhibited the proliferation as well as metastasis of PC cells. Meanwhile, MACC1-AS1 upregulated the expression of PAX8 protein, which promoted aerobic glycolysis and activated NOTCH1 signaling. Additionally, PAX8 was upregulated in PC tissues, which was correlated with the expression of MACC1-AS1 and the overall survival of PC patients. Conclusions Together, our findings indicate a critical role of MACC1-AS1/PAX8/NOTCH1 signaling, which may be an alternative treatment target in PC therapy. Electronic supplementary material The online version of this article (10.1186/s13046-019-1332-7) contains supplementary material, which is available to authorized users.

show abstract

Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy

Cited by 32 publications

References 135 publications

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas

Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions

RETRACTED ARTICLE: Long non-coding RNA MACC1-AS1 promoted pancreatic carcinoma progression through activation of PAX8/NOTCH1 signaling pathway

Contact Info

Product

Resources

About